Literature DB >> 1386836

Increased phospholipase A2 activity in peritoneal leukocytes in rat experimental colitis.

S N Murthy1, R J Biondi.   

Abstract

Activated leukocytes in the peritoneal cavity have been shown to release phospholipase A2(PLA2) activity and increased production of eicosanoids. It is not known whether a similar phenomenon occurs in inflammatory bowel diseases. We measured PLA2 activity in the peritoneal leukocytes and eicosanoid content in the peritoneal cavity of rats with experimental colitis induced by dinitrochlorobenzene, immune complex-mediated colitis, and acetic acid-induced colitis. In all models of colitis, proteins in the peritoneal cavity were increased by 60-260% above control, leukocyte number was elevated by 3- to 10-fold, the PLA2 activity by 4- to 32-fold, and anti-PLA2 activity was absent. Eicosanoid concentrations were 3- to 4-fold higher than controls. In vitro studies confirmed that the peritoneal leukocytes were the source of PLA2. Treatment of rats with dexamethasone and leukocytes in vitro reduced PLA2 significantly, but they were well above control rats without colitis. However, dexamethasone did not improve the histology. These studies suggest that peritoneal leukocytes may serve as an additional source of inflammatory mediators, which may further enhance the inflammatory response in the rat colon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386836     DOI: 10.1007/bf00918815

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  18 in total

1.  Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

2.  Cytoprotection by prostaglandins.

Authors:  A Robert
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

3.  Hydrogen peroxide-induced alterations in prostaglandin secretion in the rat colon in vitro.

Authors:  S N Murthy; C G Cooney; H R Clearfield
Journal:  Inflammation       Date:  1990-12       Impact factor: 4.092

4.  Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease.

Authors:  D W Harris; P R Smith; C H Swan
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

5.  Hypersensitive prostaglandin and thromboxane response to hormones in rabbit colitis.

Authors:  R D Zipser; J B Patterson; H W Kao; C J Hauser; R Locke
Journal:  Am J Physiol       Date:  1985-10

6.  Experimental models for ulcerative colitis.

Authors:  A B Onderdonk
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

7.  A cell-mediated immune model of inflammatory bowel disease in the rabbit.

Authors:  B S Rabin; S J Rogers
Journal:  Gastroenterology       Date:  1978-07       Impact factor: 22.682

8.  Distinct inhibition of membrane-bound and lysosomal phospholipase A2 by glucocorticoid-induced proteins.

Authors:  P Ghiara; R Meli; L Parente; P Persico
Journal:  Biochem Pharmacol       Date:  1984-05-01       Impact factor: 5.858

9.  Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Digestion       Date:  1988       Impact factor: 3.216

10.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

View more
  2 in total

1.  Phospholipase A2 activating protein and idiopathic inflammatory bowel disease.

Authors:  J W Peterson; W D Dickey; S S Saini; W Gourley; G R Klimpel; A K Chopra
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

Review 2.  Animal models of inflammatory bowel disease.

Authors:  M A Bhatti; H J Hodgson
Journal:  Int J Exp Pathol       Date:  1995-10       Impact factor: 1.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.